Combinatorial-designed Hyaluronic Acid Nanoparticles for Tumour Targeted Drug and Small Interfering Ribonucleic Acid Delivery - Hyaluronic Acid for Biomedical and Pharmaceutical Applications - page 72

cisplatin loaded HA-ODA nanoparticles, with and without PEG,
demonstrated slightly better IC 50 when compared with cisplatin alone
in resistant A549 DDP NSCLC cells.

a

HA-SP:siRNA 54:1 HA-SP:siRNA 45:1 or 27:1 or 9:1

1.2
1

1.2
1

0.8
0.6
0.4
0.2
0

0.8
0.6
0.4
0.2
0

*

*

b HA-PEI:siRNA 54:1

HA-PEI:siRNA 45:1 or 27:1 or 9:1

1.4

1.4

1.2

1.2

1
0.8
0.6
0.4
0.2
0

1
0.8
0.6
0.4
0.2
0

* *

*

Figure 3.5 HA-SP and HA-PEI/siRNA- mediated PLK1 gene
silencing in MDA-MB 468 cells. Cells were treated with polo-
like kinase (PLK1) or control (CTL) siRNA formulated HA-SP
(a) or HA-PEI (b) at polymer:siRNA mass ratios of 54:1 (a and
b, left hand figures) or 45:1 or 27:1 or 9:1 (a and b, right hand
figures), respectively for 48 h at 300, 200, 100, 50 and 10 nm
siRNA concentrations. The PLK1 gene expression was measured
by quantitative polymerase chain reaction (qPCR) and normalised
to human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH)
gene expression. Data represented as a mean ± SD (n = 3).
* P = 0.01 compared to PBS and CTL treatment groups for a and
b. ** P = 0.02 compared to PBS and CTL treatment groups for b.
Adapted from S. Ganesh, A.K. Iyer, D.V. Morrissey and
M.M. Amiji, Biomaterials , 2013, 34 , 3489 [19]